|  | CD4 Count | Nadir CD4 |  |  | ||
---|---|---|---|---|---|---|---|
(A) Control group | Transcript | Spearman r | p-value | Spearman r | p-value | Â | Â |
CCL2 | −0.00296 | 0.986 | 0.156 | 0.358 |  |  | |
CXCL5 | 0.0385 | 0.821 | 0.101 | 0.553 | Â | Â | |
IL6 | −0.0236 | 0.877 | 0.0424 | 0.799 |  |  | |
IL8 | 0.0234 | 0.891 | 0.227 | 0.176 | Â | Â | |
NRGN | −0.186 | 0.278 | −0.172 | 0.309 |  |  | |
 |  | CD4 Count | Nadir CD4 |  |  | ||
(B) LVL group | Transcript | Spearman r | p-value | Spearman r | p-value | Â | Â |
CCL2 | −0.281 | 0.133 | −0.193 | 0.283 |  |  | |
CXCL5 | 0.025 | 0.895 | −0.026 | 0.883 |  |  | |
IL6 | −0.488 | 0.006* | −0.185 | 0.304 |  |  | |
IL8 | −0.219 | 0.246 | −0.143 | 0.427 |  |  | |
NRGN | 0.41 | 0.024* | 0.314 | 0.074 | Â | Â | |
(C) HVL group | Â | CD4 Count | Nadir CD4 | Viral load | |||
Transcript | Spearman r | p-value | Spearman r | p-value | Spearman r | p-value | |
CCL2 | −0.022 | 0.918 | −0.084 | 0.695 | 0.202 | 0.355 | |
CXCL5 | −0.277 | 0.190 | −0.367 | 0.078 | 0.190 | 0.385 | |
IL6 | −0.324 | 0.122 | −0.414 | 0.044* | −0.199 | 0.364 | |
IL8 | −0.495 | 0.014* | −0.609 | 0.001** | −0.085 | 0.670 | |
NRGN | 0.224 | 0.292 | 0.153 | 0.475 | 0.143 | 0.516 |